Meiji Seika Pharma to partner with Serum Institute for Japanese Encephalitis Vaccine

Tokyo [Japan], August 24 (ANI): Japanese pharmaceutical main Meiji Seika Pharma Co., Ltd. is about to collaborate with the Serum Institute of India (SII) to fabricate and market the Japanese Encephalitis (JE) vaccine in India, in a transfer aimed toward deepening India-Japan pharmaceutical ties.
The event follows a gathering between Union Commerce and Trade Minister Piyush Goyal and Toshiaki Nagasato, President and Consultant Director of Meiji Seika Pharma.
Talking to ANI in an unique interview after the assembly, Nagasato mentioned Meiji already has a producing presence in India via its subsidiary, Medreich Restricted, based mostly in Bengaluru. He mentioned Medreich provides generic medicines globally, together with to the UK, Canada, and different international locations throughout Europe and Africa, and that the corporate is scaling up its manufacturing capability.
On the vaccine partnership, Nagasato mentioned Meiji has a know-how collaboration with SII and intends to switch the know-how for its Japanese Encephalitis vaccine at the moment marketed in Japan by its subsidiary, KM Biologics Co., Ltd. to the Indian agency. He mentioned SII is anticipated to use for regulatory approval in India as early as subsequent yr, after which the vaccine could be made obtainable to youngsters within the nation.
“We won’t say how a lot we’re planning to put money into India, as we’re nonetheless on the technique stage,” Nagasato mentioned, including that Meiji had urged the minister to assist speed up the approval course of for the vaccine in India.
He expressed confidence that SII, identified for manufacturing vaccines at a number of the lowest prices globally, would be capable to launch the JE vaccine at an inexpensive worth. He additionally famous that technical officers from SII had already visited Japan to review the underlying vaccine know-how as a part of the collaboration.
Asserting the assembly on X, Goyal mentioned the dialogue centred on strengthening India-Japan cooperation within the pharmaceutical sector and exploring avenues to develop the corporate’s manufacturing and R&D footprint in India. He added that India’s pharmaceutical ecosystem gives important alternatives for Japanese companions to scale up and obtain long-term development. (ANI)